Signals of gastric cancer recurrence and metastasis

Share This Post

Gastric cancer patients

Introduction: After clinical treatment of gastric cancer patients, in order to prevent recurrence and metastasis in the rehabilitation process, how can early detection of recurrence be done? What are the signs of relapse and metastasis? What items are reviewed regularly after discharge?

After being diagnosed with gastric cancer, after clinical treatment (surgery, chemotherapy, Chinese medicine), the tumor on the body seemed to disappear, and the gastroscope could not be seen, and CT, MRI and other examinations could not be found. In fact, it was just eliminated. Masses of cancerous tissue that can be seen by the naked eye. At this time, there are still some tiny, invisible cancer cells in the body. These cancer cells may be latent. Once the time is right for growth, they may germinate again. This is recurrence and metastasis. Roots.

For every gastric cancer patient, there are such hidden dangers. However, there are indeed some patients who have been cured through comprehensive rehabilitation measures during the consolidation period and never relapse; there are also some who have relapsed. As for the cause of the recurrence, it has been stated previously.

Of course, relapse and metastasis are not curable, and there are many effective treatments. However, the key is to detect relapse early and avoid metastasis; early detection and early treatment can still be cured, and there is always a way out. . How can a relapse be detected? What are the signs of relapse and metastasis? Based on our experience, the overview is as follows, please refer to it.

Signals of gastric cancer recurrence and metastasis

1. The symptoms of old stomach disease suddenly appear, upper abdominal pain, discomfort, fullness, belching, not thinking about diet, etc., and continue for a period of time. At this time, it should be suspected that the stump gastric cancer recurs.

2. Suddenly irritated dry cough, no sputum, check for other symptoms without a cold, taking anti-cold medicine does not improve, taking cough medicine has no effect, at this time should pay attention to whether there is lung metastasis, should be taken by chest radiography to exclude.

3. Suddenly one day, an unidentified lymphadenopathy appeared on the left supraclavicular fossa. Because the first stop of distant lymph node metastasis of gastric cancer is often found here, it is necessary to ask the doctor to rule out whether it is a recurrence of gastric cancer.

4. Unexplained black stools, like tar, and so on for a few days, cannot be explained by eating animal blood, etc. At this time, go to the hospital for examination to rule out upper gastrointestinal bleeding. Sometimes the recurrence of gastric cancer may be symptoms of upper gastrointestinal bleeding.

5. For a period of time, I suddenly felt a significant decrease in physical strength, my body was losing weight, and there was no explanation for chronic fever disease. At this time, it is often a sign of just recurring. Consult a doctor in time and carry out necessary examinations.

6. Chronic low fever occurs, the body temperature is around 38 degrees every day, not high fever, according to the cold treatment is invalid, no signs of respiratory infections are found in the examination, at this time should also rule out the possibility of recurrence, and do the necessary examinations in time, such as gastroscopy, abdominal CT Wait.

7. Recently, I feel that my abdomen is gradually increasing, I often feel bloating, I feel fluctuating when walking, and my physical strength is obviously not as good as before. This performance is a bit of ascites. It is a manifestation of cancer spreading to the abdominal cavity.

Regular review helps prevent recurrence and metastasis

Regular review is to find asymptomatic recurrence and metastasis in time, so as to obtain the opportunity for effective treatment. The relapse is not terrible, the fear is that it is found too late, and has been transferred all over the body. Therefore, it is necessary to review regularly.

What items are reviewed regularly after discharge?

1. CT: 1 month after surgery, recheck CT at the beginning of chemotherapy, recheck at the end of chemotherapy, and recheck CT 6 months after the end of chemotherapy. When discharged, CT is preferred to understand the surrounding lymph nodes. CT is reviewed every six months within the first year after discharge.

2. Gastroscopy: Gastroscopy is recommended every six months for the first year after discharge from the hospital. Gastroscopy is reviewed every 1 to 3 years; gastroscopy can promptly detect the condition of the surgical stump.

3. Blood test: CEA, blood routine. CEA is a non-specific cancer marker of gastric cancer, which can partially reflect the recurrence of gastric cancer; anemia is a symptom of gastric cancer, which should be detected and treated in time. Therefore, we recommend that the review be conducted every six months for the first 2 years after discharge.

4. Stool occult blood examination: Gastric cancer often has a small amount of bleeding, so stool occult blood is positive. We recommend rechecking every six months after discharge for the first 2 years.

Subscribe To Our Newsletter

Get updates and never miss a blog from Cancerfax

More To Explore

Lutetium Lu 177 dotatate is approved by USFDA for pediatric patients 12 years and older with GEP-NETS

Lutetium Lu 177 dotatate is approved by USFDA for pediatric patients 12 years and older with GEP-NETS

Lutetium Lu 177 dotatate, a groundbreaking treatment, has recently received approval from the US Food and Drug Administration (FDA) for pediatric patients, marking a significant milestone in pediatric oncology. This approval represents a beacon of hope for children battling neuroendocrine tumors (NETs), a rare but challenging form of cancer that often proves resistant to conventional therapies.

Nogapendekin alfa inbakicept-pmln is approved by the USFDA for BCG-unresponsive non-muscle invasive bladder cancer
Bladder cancer

Nogapendekin alfa inbakicept-pmln is approved by the USFDA for BCG-unresponsive non-muscle invasive bladder cancer

“Nogapendekin Alfa Inbakicept-PMLN, a novel immunotherapy, shows promise in treating bladder cancer when combined with BCG therapy. This innovative approach targets specific cancer markers while leveraging the immune system’s response, enhancing the efficacy of traditional treatments like BCG. Clinical trials reveal encouraging results, indicating improved patient outcomes and potential advancements in bladder cancer management. The synergy between Nogapendekin Alfa Inbakicept-PMLN and BCG heralds a new era in bladder cancer treatment.”

Need help? Our team is ready to assist you.

We wish a speedy recovery of your dear and near one.

Start chat
We Are Online! Chat With Us!
Scan the code

Welcome to CancerFax !

CancerFax is a pioneering platform dedicated to connecting individuals facing advanced-stage cancer with groundbreaking cell therapies like CAR T-Cell therapy, TIL therapy, and clinical trials worldwide.

Let us know what we can do for you.

1) Cancer treatment abroad?
2) CAR T-Cell therapy
3) Cancer vaccine
4) Online video consultation
5) Proton therapy